Tumor-selective E1a and E1b mutants
Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a recombinant adenovirus comprising a modified E1a regulatory sequence, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted, and wherein said pharmaceutical composition is free of cellular material removed by passing through a 0.4 micron filter.
2. The pharmaceutical composition of claim 1 , wherein at least one nucleotide in the range of −305 to −141 is retained.
3. The pharmaceutical composition of claim 1 , wherein at least one of Pea3 II, Pea3 III, Pea3 IV, and Pea3 V, or a functional portion thereof is deleted.
4. The pharmaceutical composition of claim 3 , wherein Pea3 II or a functional portion thereof, and Pea3 III or a functional portion thereof is deleted.
5. The pharmaceutical composition of claim 3 , wherein Pea3 IV or a functional portion thereof, and Pea3 V or a functional portion thereof is deleted.
6. The pharmaceutical composition of claim 1 , wherein said recombinant adenovirus comprises deletion of nucleotides located upstream of a E1a initiation site, wherein the deletion comprises nucleotide −393 to −304, nucleotide −305 to −255, nucleotide −270 to −240, nucleotide −299 to −293, nucleotide −270 to −265, nucleotide −299 to −293, or nucleotide −270 to −265.
7. The pharmaceutical composition of claim 1 , wherein said recombinant virus selectively expresses an E1a isoform, wherein the sequence encoding the E1a isoform is operably linked to said modified E1a regulatory sequence.
8. The pharmaceutical composition of claim 7 , wherein said recombinant adenovirus selectively expresses E1a-12S or E1a13S.
9. The pharmaceutical composition of claim 1 , wherein said recombinant adenovirus substantially excludes expression of an E1a isoform, wherein said sequence encoding said E1a isoform is operably linked to said modified E1a regulatory sequence.
10. The pharmaceutical composition of claim 9 , wherein said excluded E1a isoform is E1a-12S or E1a-13S.
11. A method of treating cancer, said method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 1 .
12. The method of claim 11 , wherein at least one nucleotide in the range of −305 to −141 is retained.
13. The method of claim 11 , wherein at least one of Pea3 II, Pea3 III, Pea3 IV, and Pea3 V, or a functional portion thereof is deleted.